By Byron Kaye SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight ...

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls ...

ResMed Inc. (RMD), headquartered in San Diego, California, specializes in designing and delivering medical devices and cloud-connected software for the healthcare sector. With a market cap of $33.6 ...

SAN DIEGO – Resmed reported revenue increased 11% to $1.4 billion for its second quarter of fiscal year 2026. Other financial results: Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 ...

7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep. 18% of couples reported sleeping in separate rooms due to snoring and restlessness. Women report ...

Medical device company ResMed (NYSE:RMD) in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit ...

Analysts estimate that ResMed will report an earnings per share (EPS) of $2.71. The announcement from ResMed is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...